PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism - ASND0035
Latest Information Update: 25 Mar 2026
At a glance
- Drugs Palopegteriparatide (Primary)
- Indications Hypoparathyroidism
- Focus Registrational; Therapeutic Use
- Acronyms PaTHway Adolescent
- Sponsors Ascendis Pharma Bone Diseases
Most Recent Events
- 25 Mar 2026 New trial record